Celebrate our 150th anniversary with fantastic savings on a joint magazine and IC Advantage subscription.
Alizyme shares got their second beating this year, plummeting over 40 per cent to record lows after its irritable bowel syndrome treatment, Colal-Pred, failed to indicate effectiveness relative to standard treatment.
Advertising
At 9p, the company's share price has fallen 90 per cent in the past 12 months. This latest setback comes after its other IBS treatment, Renzapride, also failed to achieve a positive outcome in a late-stage clinical trial.
At this stage, the pressure is still squarely on Alizyme's weight loss drug, cetilistat, to deliver results. Alizyme is well funded, but the market has lost all faith in the story, making the shares cheap. If you are in, there is still a glimmer of hope, but it's double-or-bust stuff now. Fairly priced.
Free access to financial data, charts, portfolio tools and more - registration is quick, secure and free!
Profit from IC share tips; discover the benefits of IC Advantage and sign up for a free trial.
© The Financial Times Limited 2010. All rights reserved. "Investors Chronicle", "FT" and "Financial Times" are trademarks of The Financial Times Limited. No part of these web pages may be reproduced or transmitted to or stored in any other website or other form of electronic retrieval system, without prior permission in writing from the editor.
Warning: Do remember, particularly if you are new to stock market investment that the prices of shares and other investments can fall sharply. You may not get back the money you originally invested. The material here is for general information only and is not intended to be relied upon for individual investment decisions. Take independent advice before making such decisions. This site is aimed at UK residents only. To read more please see our Important Warning
v6.2.10.5 running on www.investorschronicle.co.uk
